Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus

Diabetes Obes Metab. 2024 Oct;26(10):4787-4790. doi: 10.1111/dom.15823. Epub 2024 Aug 2.

Authors

Yusuke Baba¹, Suzuka Watanabe², Saho Hayashi¹, Toshiki Sakai¹, Masamitsu Naka¹, Saori Kami¹, Kiichi Hirayama¹, Kazuko Koizumi¹, Ai Takahashi¹, Miwako Meguro¹, Ryo Iga¹, Yoshitaka Yamanaka³, Masaaki Kataoka⁴, Daigaku Uchida^{1

5}, Ryoichi Ishibashi^{1

2}

Affiliations

¹ Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, Chiba, Japan.
² Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
³ Department of Rehabilitation, Kimitsu Chuo Hospital, Chiba, Japan.
⁴ Department of Surgery, Kimitsu Chuo Hospital, Chiba, Japan.
⁵ Department of Internal Medicine, Hotaruno Central Naika, Chiba, Japan.

PMID: 39091271
DOI: 10.1111/dom.15823

No abstract available

Keywords: GLP‐1 analogue; antidiabetic drug; antiobesity drug; appetite control; attitudes; semaglutide.

MeSH terms

Aged
Diabetes Mellitus, Type 2* / drug therapy
East Asian People
Feeding Behavior
Female
Glucagon-Like Peptides* / therapeutic use
Glycated Hemoglobin / analysis
Glycated Hemoglobin / drug effects
Glycated Hemoglobin / metabolism
Humans
Hypoglycemic Agents* / therapeutic use
Japan / epidemiology
Male
Middle Aged
Patient Satisfaction*
Treatment Outcome

Substances

Glucagon-Like Peptides
Glycated Hemoglobin
Hypoglycemic Agents
semaglutide